- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01455090
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected With Hepatitis C Virus Genotype 1
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Clichy Cedex, Frankrike, 92118
- Local Institution
-
Creteil Cedex, Frankrike, 9410
- Local Institution
-
Limoges, Frankrike, 87042
- Local Institution
-
Marseille Cedex 08, Frankrike, 13285
- Local Institution
-
Paris Cedex 14, Frankrike, 75679
- Local Institution
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294
- The Kirklin Clinic
-
-
California
-
Coronado, California, Förenta staterna, 92118
- Southern California Research Center
-
Los Angeles, California, Förenta staterna, 90073
- VA Greater Los Angeles Healthcare System
-
Los Angeles, California, Förenta staterna, 90036
- Peter J Ruane Md Inc
-
San Diego, California, Förenta staterna, 92105
- Research and Education, Inc.
-
San Diego, California, Förenta staterna, 92123
- Medical Associates Research Group
-
San Diego, California, Förenta staterna, 92114
- Precision Research Institute, LLC
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- University of Colorado Denver and Hospital
-
-
District of Columbia
-
Washington, D.C., District of Columbia, Förenta staterna, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Orlando, Florida, Förenta staterna, 32803
- Orlando Immunology Center
-
South Miami, Florida, Förenta staterna, 33143
- Miami Research Associates
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30308
- Atlanta Gastroenterology Associates, LLC
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21202
- Mercy Medical Center, Inc.
-
Lutherville, Maryland, Förenta staterna, 21093
- Johns Hopkins University
-
-
New Jersey
-
Hillsborough, New Jersey, Förenta staterna, 08844
- ID Care
-
-
New Mexico
-
Santa Fe, New Mexico, Förenta staterna, 87505
- Southwest CARE Center
-
-
New York
-
The Bronx, New York, Förenta staterna, 10468
- James J Peters VAMC
-
-
Oklahoma
-
Tulsa, Oklahoma, Förenta staterna, 74104
- Options Health Research, LLC
-
Tulsa, Oklahoma, Förenta staterna, 74135
- Healthcare Research Consultants
-
-
Texas
-
Arlington, Texas, Förenta staterna, 76012
- Texas Clinical Research Institute
-
Houston, Texas, Förenta staterna, 77030
- Research Specialists of Texas
-
San Antonio, Texas, Förenta staterna, 78215
- Alamo Medical Research
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84106
- Lifetree Clinical Research
-
-
Virginia
-
Fairfax, Virginia, Förenta staterna, 22031
- Metropolitan Research
-
Falls Church, Virginia, Förenta staterna, 22042
- Inova Fairfax Hospital
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53715
- Dean Clinic
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Fundacion De Investigacion de Diego
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Men and women, ages ≥18 years of age
- Subjects who are naive to HCV treatment, defined as no previous exposure to an Interferon (IFN), Ribavirin (RBV); or any HCV-specific direct acting antiviral or experimental therapy or subjects who are null responders to previous pegylated Interferon alfa (pegIFNα) plus Ribavirin (RBV) treatment
Subjects should have chronic hepatitis C (CHC) as documented by:
- Positive for anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least 6 months prior to screening, and positive for HCV RNA and Anti-HCV antibody at the time of screening, or
- Positive for anti-HCV antibody and HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed prior to enrollment with evidence of CHC disease, such as the presence of fibrosis)
- HCV genotype 1a, 1b or 4 only
- HCV RNA viral load of ≥10,000 IU/mL at screening
Have one of the following:
- Documented Fibrotest score of ≤0.72 and aspartate transferase (transminase) to platelet ratio index (APRI) ≤2; OR
- Documented liver biopsy within 36 months preceding Day 1 showing absence of cirrhosis OR
- Documented Fibroscan® ultrasound (where approved) within 12 months of screening showing absence of cirrhosis
- Body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive
- Subjects with compensated Child-Pugh A cirrhosis as documented by history of cirrhosis with any prior liver biopsy or Fibroscan® ultrasound (where approved) within 12 months prior to screening
Exclusion Criteria:
- Evidence of a medical condition associated with chronic liver disease other than HCV (such as but not limited to: hemochromatosis, autoimmune hepatitis,metabolic liver disease, alcoholic liver disease, toxin exposures)
- History of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis
- Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment
- Documented or suspected hepatocellular carcinoma (HCC)
- Positive for hepatitis B surface antigen (HBsAg)
- Positive for Human Immunodeficiency Virus-1 (HIV-1) and/or Human Immunodeficiency Virus-2 (HIV-2) antibodies
- Alanine transferase (transminase) (ALT) >5x upper limit of normal (ULN)
- Total Bilirubin ≥2 mg/dL
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)
BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks BMS-790052 60 mg tablet by mouth once daily for 24 Weeks BMS 791325 75 mg table by mouth twice daily for 24 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 60 mg tablet by mouth once daily for 12 Weeks BMS 791325 75 mg table by mouth twice daily for 12 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)
* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2 BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks BMS-790052 60 mg tablet by mouth once daily for 24 Weeks BMS 791325 150 mg table by mouth twice daily for 24 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)
* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2 BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 60 mg tablet by mouth once daily for 12 Weeks BMS 791325 150 mg table by mouth twice daily for 12 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)
* Genotype 1 treatment-naive subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 75 mg table by mouth twice daily for 12 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)
* Genotype 1 treatment-naive subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 150 mg table by mouth twice daily for 12 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)
* Genotype 4 treatment-naive subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 75 mg table by mouth twice daily for 12 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)
* Genotype 4 treatment-naive subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 150 mg table by mouth twice daily for 12 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)
* Genotype 1 treatment-null/non-responder subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 75 mg table by mouth twice daily for 12 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)
* Genotype 1 treatment-null/non-responder subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 150 mg table by mouth twice daily for 12 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)
* Genotype 1 treatment-null/non-responder subjects BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks BMS 791325 75 mg table by mouth twice daily for 24 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)
* Genotype 1 treatment-null/non-responder subjects BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks BMS 791325 150 mg table by mouth twice daily for 24 Weeks |
Andra namn:
Andra namn:
|
Experimentell: Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV
* Genotype 1 treatment-naive subjects BMS-650032 200 mg tablets orally twice daily 12 weeks BMS-790052 30 mg tablets orally twice daily 12 weeks BMS-791325 75 mg tablets orally twice daily 12 weeks Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks [if subject is < 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM] |
Andra namn:
Andra namn:
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Sustained virologic response (SVR) at 12 weeks post-treatment (SVR12)
Tidsram: 12 weeks post-treatment
|
12 weeks post-treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Proportion of subjects with HCV ribonucleic acid (RNA) < limit of quantification (LOQ) (detectable and undetectable)
Tidsram: Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment
|
Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment
|
|
Proportion of subjects with HCV ribonucleic acid (RNA) undetectable
Tidsram: Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment
|
Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment
|
|
Proportion of subjects who experience viral breakthrough
Tidsram: Formal analysis at SVR12, Week 48 of follow up period (or upon occurrence)
|
viral breakthrough defined as:
|
Formal analysis at SVR12, Week 48 of follow up period (or upon occurrence)
|
Proportion of subjects who experience viral relapse defined as confirmed quantifiable HCV RNA ≥ 25 IU/mL (>LOQ) in a subject with HCV RNA < LOQ or undetectable at End of treatment (EOT)
Tidsram: End of treatment (Maximum up to 24 Weeks)
|
End of treatment (Maximum up to 24 Weeks)
|
|
Maximum observed plasma concentration (Cmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Tidsram: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Observed plasma concentration at 12 hours (C12) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Tidsram: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Observed plasma concentration at 24 hours (C24) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Tidsram: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Trough observed plasma concentration (Ctrough) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Tidsram: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Time of maximum observed plasma concentration (Tmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Tidsram: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Tidsram: Day 1 and Day 14
|
Day 1 and Day 14
|
|
HCV genomic substitutions associated with exposure of BMS-650032, BMS-790052, and BMS-791325
Tidsram: At the time of viral breakthrough or relapse
|
At the time of viral breakthrough or relapse
|
|
Frequency of deaths, serious adverse events (SAEs), discontinuations due to adverse events (AEs), severity Grade 3/4 AEs, and severity Grade 3/4 laboratory abnormalities
Tidsram: Formal analysis at week 48 of follow up period (or upon occurrence)
|
Formal analysis at week 48 of follow up period (or upon occurrence)
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF. Daclatasvir + asunaprevir + beclabuvir +/- ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2016 Feb;36(2):189-97. doi: 10.1111/liv.12964. Epub 2015 Dec 6.
- Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014 Feb;146(2):420-9. doi: 10.1053/j.gastro.2013.10.057. Epub 2013 Oct 30.
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Blodburna infektioner
- Smittsamma sjukdomar
- Leversjukdomar
- Flaviviridae-infektioner
- Hepatit, Viral, Human
- Enterovirusinfektioner
- Picornaviridae-infektioner
- Hepatit, kronisk
- Hepatit
- Hepatit A
- Hepatit C
- Hepatit C, kronisk
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Antimetaboliter
- Proteashämmare
- Ribavirin
- Asunaprevir
Andra studie-ID-nummer
- AI443-014
- 2011-002788-11 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kronisk hepatit C
-
Clínica de Oftalmología de Cali S.AAvslutadMeibomisk körteldysfunktion | Eyes Dry ChronicColombia
-
Alcon ResearchAvslutad
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekryteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Dhulikhel HospitalKathmandu University School of Medical SciencesIndragenPostoperativ analgesi | CSOM - Chronic Suppurative Otitis MediaNepal
-
Dokuz Eylul UniversityEge UniversityAvslutadMMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/CKalkon
-
Tripep ABInovio PharmaceuticalsOkändKronisk hepatit C-virusinfektionSverige
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsIndragenKronisk hepatit C-virusinfektionIsrael
-
Hadassah Medical OrganizationOkändKronisk hepatit C-virusinfektionIsrael
-
Johann Wolfgang Goethe University HospitalAvslutad
-
Trek Therapeutics, PBCAvslutadKronisk hepatit C | Hepatit C genotyp 1 | Hepatit C (HCV) | Hepatit C virusinfektionFörenta staterna, Nya Zeeland
Kliniska prövningar på BMS-791325
-
Bristol-Myers SquibbAvslutad
-
Bristol-Myers SquibbIndragen
-
Bristol-Myers SquibbAvslutadHepatit C-virusKorea, Republiken av, Taiwan, Ryska Federationen
-
Timothy Morgan, MDBristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...Avslutad
-
Bristol-Myers SquibbAvslutadHepatit CFörenta staterna, Australien, Kanada, Frankrike, Puerto Rico
-
Bristol-Myers SquibbAvslutadHepatit CFörenta staterna
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...Avslutad
-
Bristol-Myers SquibbAvslutad
-
Bristol-Myers SquibbAvslutadHepatit CFörenta staterna, Australien, Kanada, Frankrike